ATAtsushi Takamatsu

Atsushi Takamatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Atsushi Takamatsu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuto Kozaka

    Department of Radiology Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa Japan

    3 shared publications
  • Kotaro Yoshida

    Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

    3 shared publications
  • Satoshi Kobayashi

    Department of Radiology Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa Japan

    3 shared publications
  • Toshifumi Gabata

    Department of Radiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

    3 shared publications
  • Azusa Kitao

    Faculty of Health Sciences Institute of Medical Pharmaceutical and Health Sciences Kanazawa University Kanazawa Ishikawa Japan

    2 shared publications
  • Dai Inoue

    Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

    2 shared publications

Latest Publications

  • Open Access

    CT-based biological age as a biomarker of aging and age-related disease assessment

    by Qian Yu, Shouhei Hanaoka, Yukihiro Nomura, Takahiro Nakao, Tomomi Takenaga, Atsushi Takamatsu, Takeharu Yoshikawa, Osamu Abe, Shenghong Ju

  • Open Access

    Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-derived cancer and concomitant pancreatic ductal adenocarcinoma

    by Fumihito Toshima, Dai Inoue, Kazuto Kozaka, Norihide Yoneda, Takahiro Komori, Atsushi Takamatsu, Yuichi Chujo, Satoshi Kobayashi

    The detection of pancreatic cystic lesions (PCLs) has increased markedly with the widespread use of cross-sectional imaging. Although the true proportion of intraductal papillary mucinous neoplasms (IPMNs) among PCLs remains uncertain, IPMN is considered to account for most PCLs and is a representative precursor lesion of pancreatic ductal adenocarcinoma (PDAC). However, not all PCLs should be assumed to represent IPMN, because this assumption may lead to unnecessary surveillance or overtreatment. Therefore, radiologists should first determine whether a PCL truly represents IPMN, particularly by differentiating it from lesions without malignant potential, such as serous cystic neoplasm. Once IPMN is diagnosed, appropriate risk stratification is required to identify IPMN-derived cancer, defined in this review as IPMN with high-grade dysplasia or associated invasive carcinoma. High-risk stigmata and worrisome features proposed in current guidelines are central to this assessment. However, the risk associated with each factor is not uniform; therefore, risk assessment and management decisions should consider both the number of risk factors present and the relative weight of each factor. Concomitant PDAC may also arise separately from the PCL, possibly reflecting a field defect of the entire pancreas. Unlike IPMN-derived cancer, concomitant PDAC may develop independently of cyst size or growth and is often detected at an advanced stage. Therefore, surveillance of patients with IPMN should include not only evaluation of the PCL itself and assessment for IPMN-derived cancer, but also systematic assessment of the entire pancreas for concomitant PDAC. This review discusses the differential diagnosis of PCLs, imaging assessment of IPMN-derived cancer, the concept and imaging clues of concomitant PDAC, and practical considerations for surveillance strategies.

  • Open Access

    Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study

    by Hirohito Osanai, Kazuto Kozaka, Takashi Matsubara, Norihide Yoneda, Takahiro Ogi, Kenichiro Okumura, Atsushi Takamatsu, Azusa Kitao, Shintaro Yagi, Taro Yamashita, et al.

    Aim: To evaluate the frequency, imaging characteristics, associated factors, and clinical significance of biliary abnormalities on imaging in patients receiving lenvatinib (LEN) plus cisplatin hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC). Methods: This retrospective single‐center study included 62 patients with HCC treated with LEN + Cisplatin HAIC. Three radiologists reviewed dynamic contrast‐enhanced CT and gadoxetic acid‐enhanced MRI to identify biliary findings. The incidence, associated factors, and clinical courses were examined. Results: Sixty‐two patients with HCC underwent 295 CT and 59 MRI examinations during a median follow‐up of 21 weeks. Biliary abnormalities were observed in 58.1% (36/62) of patients at a median of 6 weeks after treatment initiation. Hilar bile duct wall thickening occurred in 24.2% (15/62), hilar bile duct stricture in 14.5% (9/62), biloma in 1.6% (1/62), and gallbladder wall thickening in 35.5% (22/62). Initial treatment response per mRECIST was associated with biliary abnormalities (adjusted odds ratio: 5.19, p = 0.011). Symptoms developed in 22.2% (8/36) of patients with imaged biliary abnormalities. Symptom occurrence varied by imaging patterns: all 15 patients with bile duct wall thickening remained asymptomatic, whereas 40% (4/10) of those with bile duct stricture or biloma developed jaundice or cholangitis, requiring biliary interventions in three patients. Cholecystitis occurred in 18.2% (4/22) of patients with gallbladder wall thickening. Conclusions: A substantial proportion of patients treated with LEN + Cisplatin HAIC developed biliary abnormalities on imaging, particularly those with an initial treatment response. Most abnormalities were asymptomatic; however, bile duct stricture may represent a crucial imaging finding even in the absence of symptoms.

  • A Preliminary Study of a Machine Learning Prediction of Poorly Differentiated Hepatocellular Carcinoma Based on a Comprehensive Parameter Analysis Using Dual-Energy Computed Tomography

    by Atsushi Takamatsu, Norihide Yoneda, Fumihito Toshima, Taichi Kitagawa, Takahiro Komori, Dai Inoue, Azusa Kitao, Kazuto Kozaka, Osamu Matsui, Satoshi Kobayashi

    Objective: To develop and evaluate the performance of a predictive machine learning model for poorly differentiated hepatocellular carcinoma (p-HCC) using comprehensive quantitative parameters from dual-energy computed tomography (DECT). Materials and Methods: We retrospectively analyzed 181 surgically resected, pathologically proven HCCs in 170 patients who had undergone preoperative DECT between April 2019 and November 2025. After propensity-score matching on age, sex, alpha-fetoprotein (AFP), tumor size on CT, and LI-RADS categories, the dataset was divided into a training set including 51 HCCs (17 p-HCCs and 34 non-p-HCCs) from 2019 to 2022 and a testing set including 33 HCCs (11 p-HCCs, 22 non-p-HCCs) from 2023 to 2025. Overall, 3516 DECT parameters were extracted from precontrast images and three contrast-enhanced images [arterial phase (AP), portal venous phase (PVP), and delayed phase (DP)] for each case. These parameters included virtual monochromatic imaging (VMI) CT values, effective atomic numbers (Effective-Z), material density, spectral curve slopes (Slope), and interphase differences (Diff). Clinical data, including etiology of liver disease, serum AFP level, and lesion size, were collected. A machine learning model based on an extra trees classifier was trained, and a Shapley additive explanations (SHAP) analysis was performed for each selected parameter following data preprocessing. Model performance was evaluated using accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUC). Results: SHAP analysis revealed that the most highly influential features were delayed phase-related, with the average 40-keV VMI CT value in the delayed phase contributing most strongly. In addition, several Effective-Z-related features and selected material density parameters also showed substantial importance. In the testing set, the model demonstrated an accuracy, sensitivity, specificity, PPV, NPV, and AUC of 0.606, 0.818, 0.500, 0.450, 0.846, and 0.800, respectively. Conclusions: The predictive machine learning model for p-HCC showed acceptable diagnostic performance and, although still preliminary, may contribute to a noninvasive assessment of HCC differentiation grades, guiding clinical decision-making.

  • Open Access

    Visualization of Intrapulmonary Lymphadenopathy on Vessel‐Suppressed Computed Tomography in a Patient With Sarcoidosis

    by Seitaro Ishikawa, Atsushi Takamatsu, Kotaro Yoshida, Miho Okuda, Satoshi Kobayashi

    We report a case of a 55‐year‐old woman diagnosed with sarcoidosis involving multiple intrapulmonary lymph nodes that were clearly visualized on vessel‐suppressed CT imaging. Intrapulmonary lymph node involvement in patients with sarcoidosis has been reported less frequently and has not been well discussed. This may be attributed to the fact that intrapulmonary lymph nodes present as small nodular lesions located along pulmonary vessels, making them difficult to detect on conventional imaging. Vessel‐suppressed CT enhances visualization of pulmonary lesions by selectively suppressing vascular structures. This case highlights the clinical utility of vessel‐suppressed CT for improved detection of intrapulmonary lymph node lesions in the diagnosis of sarcoidosis.

  • Can solid pseudopapillary neoplasm of the pancreas without degeneration be diagnosed with imaging? a comparison study of the solid component of solid pseudopapillary neoplasm, neuroendocrine neoplasm, and ductal adenocarcinoma

    by Fumihito Toshima, Dai Inoue, Kazuto Kozaka, Takahiro Komori, Atsushi Takamatsu, Ayako Katagiri, Toshifumi Gabata

    Purpose To investigate the MR findings of the solid components within pancreatic solid pseudopapillary neoplasms (SPNs) to characterize solid SPN without degeneration. Methods After case matching, 23 patients with SPNs, 23 with pancreatic neuroendocrine neoplasms (PNENs), and 46 pancreatic ductal adenocarcinomas (PDACs) were included in this retrospective comparative study. The MR findings of the solid components within the pancreatic tumors were assessed qualitatively and semi-quantitatively. Results In the qualitative assessment, significant differences were noted in T2-weighted imaging and MR cholangiopancreatography (MRCP). SPNs with a score of 4–5 (iso- to hyper-intense compared with the renal cortex) were observed in 18/19 (94.7%) by reader 1 and 15/19 (78.9%) by reader 2 (score 5, 52.6% and 47.4%) on fast spin-echo (FSE) T2-weighted imaging. On MRCP, the two readers identified 12 (63.2%) and 8 (42.1%) SPNs, respectively. The semi-quantitative signal-intensity ratio (SIR, signal intensity of tumor/signal intensity of the pancreatic parenchyma) of SPNs on FSE T2-weighted imaging was significantly higher (mean, 1.99–2.01) than that of PNENs (1.30–1.31) or PDACs (1.26–1.28). The sensitivity/specificity of ‘hyper’ on T2-weighted imaging (qualitative score of 4–5, or SIR of ≥ 1.5) were 78.9–100.0%/63.8–79.7%. The sensitivity/specificity of ‘remarkably hyper’ (score of 5, SIR of ≥ 2.0, or visible on MRCP) or salt-and-pepper pattern were 36.8–68.4%/85.5–98.6%. Conclusion T2-weighted imaging may be the key sequence for solid SPN. Solid tumors with hyper-intensity on T2-weighted imaging (especially, more hyper-intense than the renal cortex, more than twice the signal of the pancreatic parenchyma, depicted on MRCP, or salt-and-pepper appearance) may be suspected to be SPNs.


  • Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings

    by Atsushi Takamatsu, Kotaro Yoshida, Fumihito Toshima, Kazuto Kozaka, Naho Yamamoto, Yoshimichi Sai, Toshifumi Gabata

    Pegfilgrastim-induced aortitis was more common than previously reported, with an incidence of 2.7% per patient and 1.2% per dose; therefore, radiologists should carefully monitor patients undergoin... Background Pegfilgrastim-induced aortitis is a rare but serious adverse event in patients undergoing anticancer therapy with granulocyte colony–stimulating factor analogs. Despite previous case ser...


  • Open Access

    Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men

    by Ryunosuke Nakagawa, Hiroaki Iwamoto, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Norihito Akatani, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, et al.

    Background: Treatment strategies have changed dramatically in recent years with the development of a variety of agents for metastatic hormone-naïve prostate cancer (mHNPC). There is a need to identify prognostic factors for the appropriate choice of treatment for patients with mHNPC, and we retrospectively examined these factors. Methods: Patients with mHNPC treated at our institution from 2000 to 2019 were included in this study. Overall survival (OS) was estimated retrospectively using the Kaplan–Meier method, and factors associated with OS were identified using univariate and multivariate analyses. A prognostic model was then developed based on the factors identified. Follow-up was terminated on 24 October 2021. Results: The median follow-up duration was 44.2 months, whereas the median OS was 85.2 months, with 88 patients succumbing to their disease. Multivariate analysis identified Gleason pattern (GP) 5 content, bone scan index (BSI) ≥ 1.5, and lactate dehydrogenase (LDH) levels ≥ 300 IU/L as prognostic factors associated with OS. We also developed a prognostic model that classified patients with mHNPC as low risk with no factor, intermediate risk with one factor, and high risk with two or three factors. Conclusions: Three prognostic factors for OS were identified in patients with mHNPC, namely GP5 inclusion, BSI ≥ 1.5, and LDH ≥ 300. Using these three factors, we developed a new prognostic model for OS that can more objectively predict patient prognosis.